Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 25INDUSTRY 2NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 253Pemetrexed 193Bevacizumab 190Docetaxel 188Nivolumab 182Injections 167Cyclophosphamide 147atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 128Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 77Azacitidine 74Irinotecan 73Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Data Collection × 1 year × Clear all
NCT03516110 2026-01-23

PRISME

Ipsen

Completed
831 enrolled
Genitourinary

Prostatic Neoplasms

NCT05017662 2025-09-04

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Ariceum Therapeutics GmbH

Phase NA Completed
20 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡